Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINHALATIONGeneric

ARCAPTA NEOHALER

INDACATEROL MALEATE

Standard Dose
EQ 75MCG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ARCAPTA NEOHALER is listed in Drugs@FDA under application 022383 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient INDACATEROL MALEATE Form and strength POWDER;INHALATION - EQ 75MCG BASE Sponsor NOVARTIS Submission history Latest submission status date: 2021-07-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview ARCAPTA NEOHALER is listed in Drugs@FDA under application 022383 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient INDACATEROL MALEATE Form and strength POWDER;INHALATION - EQ 75MCG BASE Sponsor NOVARTIS Submission history Latest submission status date: 2021-07-30 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.